ストックスクリーナーアプリを入手
2.91
11.49%
0.30
アフターアワーズ：
2.91
前日終値:
$2.61
開ける：
$2.64
24時間の取引高:
985.10K
Relative Volume:
1.08
時価総額：
$184.36M
収益：
$13.86M
当期純損益:
$-81.74M
株価収益率:
-2.2323
EPS:
-1.3036
ネットキャッシュフロー:
$-66.98M
1週間 パフォーマンス:
+29.33%
1か月 パフォーマンス:
+5.05%
6か月 パフォーマンス:
+77.44%
1年 パフォーマンス:
+132.80%
1日の値動き範囲:
$2.62
$2.99
1週間の範囲:
$2.125
$2.99
52週間の値動き範囲:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Compare PYXS vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
2.91 | 165.36M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Pyxis Oncology Inc (PYXS) Balance Sheet - TradingKey
Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pyxis Oncology Inc (PYXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PYXS|Pyxis Oncology Inc|Price:2.610|Chg%:-0.070 - TradingKey
Pyxis Oncology Inc (PYXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pyxis Oncology Inc (PYXS) Institutional Confidence - TradingKey
PYXS|Pyxis Oncology Inc|Price:2.600|Chg%:-0.080 - TradingKey
Pyxis Oncology Inc (PYXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PYXS stock trades steady as Pyxis Oncology highlights cash runway and clinical progress - Ad-hoc-news.de
Craig D Gordon Net Worth (2026) - GuruFocus
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Pyxis Oncology Inc. - GuruFocus
Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin - Seeking Alpha
Pyxis Oncology (PYXS) Declines 7.87% as Stock Tests Key Support Near $2.34Percent Above MA - dars.gov.et
Pyxis Oncology (PYXS) Declines Over 7%, Trading Near Critical Support LevelPassive Flow - dars.gov.et
Pyxis Oncology (NASDAQ: PYXS) sees GordonMD entities report over 10M shares and large warrant stake - Stock Titan
Biotechnology Value Fund group (NASDAQ: PYXS) reports 9.99% capped stake in Pyxis - Stock Titan
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Pyxis Oncology Company Profile & Introduction - Moomoo
PYXIS ONCOLOGY INC (PYXS) Stock Price & Overview - ChartMill
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Glaukos (GKOS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR) - The Globe and Mail
H.C. Wainwright reiterates Pyxis Oncology stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Pyxis Oncology stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Pyxis Oncology(PYXS) Stock Options Chain | Quotes & News - Moomoo
PYXS Maintains by Leerink Partners -- Price Target Lowered to $7 - GuruFocus
Pyxis Oncology Raises Capital Through Private Placement Financing - TipRanks
Pyxis Oncology (PYXS) director sells 35K shares after option exercise - Stock Titan
Pyxis Oncology Raises $50 Million in Private Placement; Warrants Could Add ~$64 Million - TradingView
Pyxis Oncology (NASDAQ: PYXS) raises up to $114M in private placement to fund MICVO trials - Stock Titan
GordonMD entities report 10,024,909 PYXS shares (PYXS) - Stock Titan
Leerink cuts Pyxis Oncology stock price target on valuation - Investing.com
Leerink cuts Pyxis Oncology stock price target on valuation By Investing.com - Investing.com India
Pyxis Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
Pyxis Oncology Secures $114M for MICVO Cancer Trial - AllSci
Pyxis Oncology, Inc. Stock 12‑Month Price Target Raised to $7.14, Implies 137% Upside - TradingView
Latham & Watkins Advises on Pyxis Oncology’s Up to US$114 Million Private Placement Financing - Legal Desire Media and Insights
William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating - Moomoo
Form 144 Pyxis Oncology For: 30 June By Investing.com - Investing.com Australia
[144] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology, Inc. (PYXS) announced the completion of a private financing agreement with a total funding amount up to 114 millions dollars. - Bitget
Pyxis OncologyExpects Updated Phase 1 Mono - Moomoo
Pyxis Oncology Announces up to $114 Million P - Moomoo
Pyxis Oncology Secures Up to $114 Million Private Placement - marketscreener.com
Pyxis Oncology (PYXS) Secures $50 Million in Private Placement F - GuruFocus
Pyxis Oncology Announces Up To $114 Million Private Placement Financing To Advance Micvo Through Key Clinical Milestones - TradingView
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):